Literature DB >> 27811071

BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.

Maria-Rosa Ghigna1,2,3, Christophe Guignabert1,2, David Montani1,2,4, Barbara Girerd1,2,4, Xavier Jaïs1,2,4, Laurent Savale1,2,4, Philippe Hervé5, Vincent Thomas de Montpréville3, Olaf Mercier1,2,5, Olivier Sitbon1,2,4, Florent Soubrier6, Elie Fadel1,2,5, Gérald Simonneau1,2,4, Marc Humbert1,2,4, Peter Dorfmüller7,2,3.   

Abstract

The impact of bone morphogenetic protein receptor 2 (BMPR2) gene mutations on vascular remodelling in pulmonary arterial hypertension (PAH) is unknown. We sought to identify a histological profile of BMPR2 mutation carriers.Clinical data and lung histology from 44 PAH patients were subjected to systematic analysis and morphometry.Bronchial artery hypertrophy/dilatation and bronchial angiogenesis, as well as muscular remodelling of septal veins were significantly increased in PAH lungs carrying BMPR2 mutations. We found that patients displaying increased bronchial artery remodelling and bronchial microvessel density, irrespective of the mutation status, were more likely to suffer from severe haemoptysis. History of substantial haemoptysis (>50 mL) was significantly more frequent in BMPR2 mutation carriers. 43.5% of BMPR2 mutation carriers, as opposed to 9.5% of noncarriers, displayed singular large fibrovascular lesions, which appear to be closely related to the systemic lung vasculature.Our analysis provides evidence for the involvement of the pulmonary systemic circulation in BMPR2 mutation-related PAH. We show that BMPR2 mutation carriers are more prone to haemoptysis and that haemoptysis is closely correlated to bronchial arterial remodelling and angiogenesis; in turn, pronounced changes in the systemic vasculature correlate with increased pulmonary venous remodelling, creating a distinctive profile in PAH patients harbouring a BMPR2 mutation.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27811071     DOI: 10.1183/13993003.00464-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  23 in total

1.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

Review 2.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

3.  Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.

Authors:  Nauman A Khan; Rizwan A Khan; Adriano R Tonelli; Kristin B Highland; Neal F Chaisson; Miriam Jacob; Rahul Renapurkar; Raed A Dweik; Gustavo A Heresi
Journal:  Chest       Date:  2019-02-15       Impact factor: 9.410

4.  Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension.

Authors:  Toshio Suzuki; Erica J Carrier; Megha H Talati; Anandharajan Rathinasabapathy; Xinping Chen; Rintaro Nishimura; Yuji Tada; Koichiro Tatsumi; James West
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-09-21       Impact factor: 5.464

Review 5.  'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.

Authors:  Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf
Journal:  Genes (Basel)       Date:  2020-11-26       Impact factor: 4.096

6.  Nanoparticle-Facilitated Gene Delivery in Congenital Pulmonary Vascular Disease: Roadmap for Other Forms of Pulmonary Hypertension.

Authors:  Jane A Leopold
Journal:  Circulation       Date:  2021-08-16       Impact factor: 39.918

7.  Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.

Authors:  Edda Spiekerkoetter; Elena A Goncharova; Christophe Guignabert; Kurt Stenmark; Grazyna Kwapiszewska; Marlene Rabinovitch; Norbert Voelkel; Harm J Bogaard; Brian Graham; Soni S Pullamsetti; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2019-11-20       Impact factor: 3.017

8.  Pulmonary venous remodeling in COPD-pulmonary hypertension and idiopathic pulmonary arterial hypertension.

Authors:  Kasper Hasseriis Andersen; Claus Bøgelund Andersen; Finn Gustafsson; Jørn Carlsen
Journal:  Pulm Circ       Date:  2017-05-24       Impact factor: 3.017

Review 9.  Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.

Authors:  Adam Andruska; Edda Spiekerkoetter
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

10.  Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.

Authors:  Charaka Hadinnapola; Marta Bleda; Matthias Haimel; Nicholas Screaton; Andrew Swift; Peter Dorfmüller; Stephen D Preston; Mark Southwood; Jules Hernandez-Sanchez; Jennifer Martin; Carmen Treacy; Katherine Yates; Harm Bogaard; Colin Church; Gerry Coghlan; Robin Condliffe; Paul A Corris; Simon Gibbs; Barbara Girerd; Simon Holden; Marc Humbert; David G Kiely; Allan Lawrie; Rajiv Machado; Robert MacKenzie Ross; Shahin Moledina; David Montani; Michael Newnham; Andrew Peacock; Joanna Pepke-Zaba; Paula Rayner-Matthews; Olga Shamardina; Florent Soubrier; Laura Southgate; Jay Suntharalingam; Mark Toshner; Richard Trembath; Anton Vonk Noordegraaf; Martin R Wilkins; Stephen J Wort; John Wharton; Stefan Gräf; Nicholas W Morrell
Journal:  Circulation       Date:  2017-09-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.